Inhibiting the recruitment of MDSCs is essential because their presence in the tumor microenvironment is associated with poor prognosis and resistance to various cancer therapies. By blocking MDSC recruitment, we can potentially enhance the efficacy of immunotherapies, chemotherapy, and other cancer treatments by lifting the immunosuppressive barrier and enabling a more effective anti-tumor immune response.
